1 not yet recruiting, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Withdrawn 1 |
Follow Guru Sonpavde: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy Zanzalintinib - Advanced Urothelial Carcinoma | Phase 2 | Not yet recruiting | Guru Sonpavde | 44 | 2026-10-01 | 2026-09-02 |
| Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma Avelumab, Sunitinib - Clear-cell Renal Cell Carcinoma, RCC | Phase 2 | Withdrawn | Guru Sonpavde | 2017-05-23 | 2022-02-15 |
Carcinoma, Renal Cell (1) · Kidney Neoplasms (1)
United States (1)